Xichun Hu
Shanghai Medical College of Fudan University(CN)Fudan University Shanghai Cancer Center(CN)Beijing Haidian Hospital(CN)
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer(2014)267 cited
- → Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial(2019)264 cited
- → Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer(2014)234 cited
- → Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial(2021)159 cited
- → PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib(2011)145 cited
- → Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis(2022)113 cited